当前位置:循环首页>正文

ACUITY试验:合并慢性肾脏疾病的急性冠脉综合征患者出血和缺血性并发症与不同糖蛋白IIb / IIIa受体抑制剂有关

Bleeding and Ischemic Complications in Patients With Acute Coronary Syndromes and Chronic Kidney Disease in Relation to Different Glycoprotein IIb/IIIa Inhibitors: Analysis From the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial

作者:国际循环网   日期:2010/12/14 10:02:33

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Olayinka Afolabi-Brown1; Eugenia Nikolsky1; Alexandra J Lansky1; Roxana Mehran1; Martin Fahy1; Brent T McLaurin2; David A Cox3; Frederick Feit4; Antonio Colombo5; Adriano Caixeta6; Gregg W Stone6

    Olayinka Afolabi-Brown1; Eugenia Nikolsky1; Alexandra J Lansky1; Roxana Mehran1; Martin Fahy1; Brent T McLaurin2; David A Cox3; Frederick Feit4; Antonio Colombo5; Adriano Caixeta6; Gregg W Stone6
1 Cardiovascular Rsch, New York, NY
2 AnMed Health, Anderson, SC
3 Mid Carolina Cardiology, Charlotte, NC
4 New York Univ Sch of Medicine, New York, NY
5 Ospedale San Raphael, Milan, Italy
6 Cardiovascular Rsch, New York, NY
    Objectives: We evaluated outcomes of moderate- to high-risk patients (pts) with acute coronary syndromes (ACS) and chronic kidney disease (CKD) receiving alternative antithrombotic therapy in the ACUITY trial.
Background: Knowledge of safety and efficacy of different antithrombotic medications is important considering the choice of therapy in pts with ACS having CKD.
    Methods: In the ACUITY trial, 2468(19.1%) pts had CKD (baseline creatinine clearance <60 ml/min) and 10,472 (80.9%) pts had preserved renal function. Pts were randomized to receive 1 of 3 antithrombotic regimens including heparin + glycoprotein IIb/IIIa inhibitors (H + GPI), bivalirudin (Biv) plus a GPI, or Biv alone. Type of GPI (abciximab or a small-molecule GPI [eptifibatide and tirofiban]) was at operator’s discretion. Dosages were adjusted for renal function. Patients treated with Biv + a GPI were excluded from this analysis.
    Results: 30-day outcomes are presented in the table. Regardless of antithrombotic regimen, CKD was associated with remarkable increase in ischemic events, and more than 2-fold increase in rates of major bleeding. In pts with CKD, there were no significant differences in rates of major bleeding among those who received H +a small-molecule GPIs vs abciximab (p=0.7). In pts with CKD, Biv monotherapy compared to H +a small-molecule GPIs resulted in remarkably lower rates of major bleeding (p=0.003) without increase in rates of ischemic events. Bivalirudin monotherapy resulted in non significantly lower rates of bleeding than H+abciximab (p=0.3).
    Conclusions: CKD is associated with higher rates of 30-day ischemic events and major bleeding. Rates of major bleeding did not differ significantly between small-molecule GPIs and abciximab when used in conjunction with heparin in pts with ACS and baseline CKD. In pts with or without CKD, bivalirudin monotherapy resulted in the lowest rates of hemorrhagic events without increasing risk of ischemic complications.

 

 

版面编辑:沈会会  责任编辑:张衡



ACUITY慢性肾脏疾病急性冠脉综合征出血并发症缺血性并发症糖蛋白IIb / IIIa受体抑制剂

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530